Second drug approved for achondroplasia
Navepegritide (Yuviwel), a C-type natriuretic peptide analog, is the second drug to be approved for the treatment of achondroplasia. It is administered subcutaneously once weekly. The retail cost for navepegritide is expected to be almost half a million dollars annually.
Authors
- Diane S. Aschenbrenner
Institutions
- Johns Hopkins University (US)
- The Dialogue (US)
Publication Details
- Journal
- AJN American Journal of Nursing
- Published
- 2026-06-25
- DOI
- https://doi.org/10.1097/ajn.0000000000000331b
- Primary Topic
- Connective tissue disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00